Vaccination with peptides (molecules) and other ingredients which stimulate the anticancer immune system in patients with advanced cancers

Registry ID

EUCTR2014-003025-18

Source registry

EUCTR

Status

Completed

Phase

PHASE1

Sponsor

King's College London

Start date

2015-01-21

Completion date

2019-07-30

Last update

2026-08-16

Conditions

• Advanced malignancies

Summary

The primary objective is to evaluate the safety, tolerability and acceptability of the vaccination protocol using hTERT peptides with adjuvants and agents inhibiting suppressor mechanisms in patients with advanced malignancies.

Locations

• , , UK

Related clinical trials

• A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies

View on source registry